On April 19, 1943, a Swiss chemist named Albert Hofmann rode his bicycle home from the Sandoz laboratory in Basel. He had deliberately ingested 250 micrograms of a compound he had synthesized five years earlier and set aside — lysergic acid diethylamide, which he had re-investigated after a curious and inexplicable altered state during its original synthesis. By the time he reached his front door, the world had transformed. Faces became grotesque masks. The familiar objects of his house shifted, contorted, and pulsed with an uncanny inner life. He was convinced, briefly, that a neighbor had become a malevolent witch. Then the terror passed and something else arrived: extraordinary visual phenomena, intense colors, an unusual depth to all perceptions, a dissolution of the ordinary boundary between himself and the room around him. The experience lasted several hours. The next morning he felt fine — physically unharmed, mentally clear, and profoundly disoriented by what he had witnessed of his own nervous system.
Hofmann's bicycle ride — now annually commemorated as "Bicycle Day" in psychedelic culture — marked the discovery of one of the most pharmacologically precise and neurobiologically informative tools in the history of neuroscience. But the compound he discovered was not understood scientifically for another six decades. It took Robin Carhart-Harris's 2012 fMRI study to provide the first brain imaging of a human under psilocybin. It took the 2019 REBUS model to provide a coherent theoretical framework for what psychedelics do to the predictive hierarchy of the brain. And it took the MAPS Phase 3 MDMA trials and the Johns Hopkins psilocybin depression studies to establish, in randomized controlled conditions, that these compounds are among the most effective treatments for psychiatric conditions that have otherwise resisted pharmacological intervention.
What happens when you take psychedelics is not random or mystical in the pejorative sense. It is the consequence of a specific pharmacological interaction with receptors in the prefrontal cortex that disrupts the brain's most fundamental organizational principle: the hierarchical dominance of prediction over perception.
Key Definitions
5-HT2A Receptor: A G-protein coupled serotonin receptor subtype located primarily on pyramidal neurons in layers II-V of the cortex, particularly the prefrontal cortex. It is the primary target of classical psychedelics — psilocybin, LSD, DMT, mescaline — and its agonism is causally necessary for the psychedelic experience.
Default Mode Network (DMN): A set of medially located cortical regions — including the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), and angular gyrus — identified by Marcus Raichle and colleagues that are most active during rest, self-referential thought, autobiographical memory retrieval, and social cognition. Sometimes described as the neural substrate of the narrative self.
Ego Dissolution: The subjective experience of the dissolution or loss of the normal sense of self as a bounded, continuous entity distinct from the environment. Ranges from mild loosening of self-boundaries to complete loss of self/other distinction. Correlates neuroimaging-wise with DMN deactivation.
REBUS Model: Relaxed Beliefs Under pSychedelics — a theoretical framework proposed by Carhart-Harris and Friston (2019) applying predictive processing theory to psychedelic action. Proposes that psychedelics reduce the influence of high-level priors (top-down predictions) relative to bottom-up sensory signals, effectively flattening the brain's predictive hierarchy.
Psychoplastogens: Compounds that promote structural neural plasticity — dendritic spine growth, axonal sprouting, synaptogenesis — independently of the hours-long psychedelic experience itself. Term coined by David Olson and colleagues (2018, Cell Reports).
Set and Setting: Timothy Leary's term for the two non-pharmacological variables that most strongly determine the quality and content of a psychedelic experience: set (mindset — the person's expectations, intentions, psychological state, and personality) and setting (the physical and social environment during the session). The concept has been validated neurobiologically by research showing that 5-HT2A agonism in prefrontal circuits increases context-sensitivity and the influence of environmental cues on the direction of associative processing.
The Pharmacology: 5-HT2A Agonism and What It Does
Classical psychedelics — psilocybin, LSD, dimethyltryptamine (DMT), mescaline, and 2C-X phenethylamines — share a primary mechanism: agonism at the 5-HT2A serotonin receptor subtype. This is not a recent discovery; the 5-HT2A connection was established in the 1990s through pharmacological challenge studies. David Nichols, the Purdue University medicinal chemist who has synthesized many of the research compounds used in contemporary psychedelic studies, confirmed that structural modifications that reduce 5-HT2A binding affinity proportionally reduce psychedelic activity.
The decisive evidence is pharmacological antagonism: pretreatment with ketanserin — a selective 5-HT2A antagonist — completely blocks the hallucinatory effects of psilocybin in human subjects (Vollenweider et al., 1998), despite the fact that psilocybin/psilocin also binds several other receptor subtypes. This establishes 5-HT2A agonism as causally necessary for the psychedelic experience, not merely correlated with it.
Where the Receptor Is and What It Does
5-HT2A receptors are expressed at highest density in pyramidal neurons of layers II/III and V of the neocortex, particularly the prefrontal cortex, cingulate cortex, and sensory association areas. They are also expressed in the thalamus, striatum, and claustrum. Activation of 5-HT2A receptors on cortical pyramidal neurons has two primary effects: it increases the spontaneous firing rate of these neurons and increases the sensitivity of the neurons to excitatory inputs, including glutamate. The net result is increased cortical glutamate tone and increased signal-to-noise in cortical processing — where "noise" means sensory content and internally generated associations that would normally be filtered before reaching conscious awareness.
In the thalamus, 5-HT2A activation disrupts the normal filtering function of thalamocortical circuits. The thalamus normally acts as a gatekeeper for sensory information entering the cortex, suppressing most of the information it receives and relaying only a narrow, prediction-consistent signal. 5-HT2A agonism loosens this filtering, allowing a broader range of sensory and associative content to reach the cortex — an account that explains both the perceptual richness of psychedelic experience and the flooding of awareness with normally-suppressed sensory detail.
The LSD "Lid Mechanism"
LSD's unusual pharmacodynamics were explained by Brian Roth and colleagues at the University of North Carolina (Wacker et al., 2017, Cell) using cryo-electron microscopy. Standard receptor-ligand binding is reversible: the drug binds the receptor, activates it, and eventually dissociates. LSD enters the 5-HT2A receptor's binding pocket and then becomes trapped by an extracellular loop that closes over it — a "lid" that the LSD molecule itself triggers. This kinetic trapping explains LSD's 8-12 hour duration: the receptor remains occupied until cellular internalization processes remove it from the membrane entirely. No other common psychedelic produces this trapping mechanism; psilocin and DMT bind and dissociate more rapidly, accounting for their shorter durations (4-6 hours for psilocybin, 15-30 minutes for smoked DMT).
Glutamate and the Cortical Excitement
A consistent finding in psychedelic neurochemistry is 5-10-fold increases in cortical glutamate release following 5-HT2A agonism. Vollenweider and colleagues' microdialysis studies in rodents and subsequent human magnetic resonance spectroscopy studies have documented this glutamate surge in the prefrontal cortex and anterior cingulate. The NMDA receptor antagonist ketamine produces superficially similar perceptual alterations through a different mechanism (blocking NMDA receptors, which has the paradoxical effect of increasing cortical glutamate through disinhibition). The convergence of psychedelic and dissociative compounds on cortical glutamate excess points to glutamatergic dysregulation as the proximate cause of perceptual disturbance, with 5-HT2A agonism as the triggering event for classical psychedelics.
The Default Mode Network and Ego Dissolution
Marcus Raichle's 2001 identification of the default mode network established that the brain does not rest when the person is resting — a specific set of regions become more active during unstructured cognitive states. These regions — most notably the posterior cingulate cortex, medial prefrontal cortex, and angular gyrus — are associated with self-referential processing, autobiographical memory, social cognition, and the construction of what psychologists call the "narrative self" — the sense of being a continuous, bounded person with a history, plans, and a distinct perspective.
Robin Carhart-Harris, Robert Leech, Peter Hellyer, Murray Shanahan, Amanda Feilding, Enzo Tagliazucchi, Diego Contreras, and David Nutt's 2012 PNAS paper, "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin," was the first neuroimaging study to directly examine psilocybin's brain effects. The study used arterial spin labeling and BOLD fMRI in 30 healthy volunteers receiving 2mg intravenous psilocybin or saline. The primary finding was dramatic: psilocybin significantly decreased blood flow and BOLD signal in medial prefrontal cortex and posterior cingulate cortex — the core DMN hubs. The magnitude of PCC deactivation correlated with participants' reports of ego dissolution intensity (r = -0.63, p < 0.001).
This correlation between DMN deactivation and ego dissolution — replicated across multiple studies, including those using LSD and ayahuasca (DMT-containing beverage) — suggests that the narrative self, as constructed moment-to-moment by DMN activity, is what is dissolved during ego dissolution. Without the DMN's continuous self-modeling, the sense of being a distinct, bounded self fades.
Enzo Tagliazucchi and colleagues' 2016 Current Biology paper, using LSD, documented an additional effect: under psychedelics, the functional segregation between large-scale brain networks — the DMN, the salience network, the executive control network — breaks down. Networks that are normally anti-correlated (when one is active, the other is suppressed) become correlated. The brain shows increased global functional connectivity and decreased within-network segregation. Carhart-Harris has described this state as a transition toward "criticality" — a state of maximal information integration between network states — which in information-theoretic terms corresponds to a brain operating near a phase transition between ordered and disordered states.
The REBUS Model: Psychedelics as Predictive Hierarchy Flatteners
Karl Friston's predictive processing (or "free energy principle") framework proposes that the brain is fundamentally a prediction machine. Rather than passively processing sensory input, the brain continuously generates predictions about the causes of sensory signals based on an internal model of the world, and perception is the result of a negotiation between top-down predictions and bottom-up prediction errors. The hierarchy is organized so that higher cortical levels maintain abstract, long-term priors, while lower levels encode shorter-timescale prediction errors. The confidence (precision) with which priors are held determines how strongly they constrain lower-level processing.
Robin Carhart-Harris and Karl Friston's 2019 REBUS paper (Pharmacological Reviews, 71(3), 316-344) proposed that 5-HT2A agonism in cortical pyramidal neurons specifically reduces the precision-weighting of higher-level priors — effectively relaxing the grip of existing beliefs, schemas, and habitual thought patterns on perception and cognition. The bottom-up, prediction-error-weighted signals from sensory processing and associative networks gain disproportionate influence over consciousness.
The model makes specific, testable predictions:
Perceptual effects: With top-down filtering reduced, normally suppressed sensory content reaches awareness — producing the richly detailed perceptions, visual noise, and synesthesia of psychedelic experience. The visual cortex operates with reduced top-down constraint, generating experience more directly from retinal input and intrinsic cortical dynamics.
Cognitive loosening: Habitual thought patterns are high-level priors. Under psychedelics, the precision of these priors is reduced, allowing associative thinking to proceed with fewer top-down constraints. This produces both the creative, wide-ranging associative thought of psychedelic experience and the loosening of pathologically rigid thought patterns (rumination, self-critical loops, craving cycles) that may explain therapeutic benefits.
Ego dissolution: The "self" in predictive processing is itself a high-level prior — a model of the agent's own body, history, and perspective that is normally maintained with high precision and used to contextualize all other predictions. Reducing the precision of this prior produces the dissolution of self-boundaries characteristic of intense psychedelic experiences.
Therapeutic mechanism: Pathological states like depression, addiction, and PTSD are characterized, on this account, by overly rigid, deeply entrenched priors that resist updating despite contradicting evidence. The depressed person's prior that they are worthless, the addicted person's prior that the substance is necessary for wellbeing, the traumatized person's prior that the world is imminently dangerous — these high-precision beliefs constrain cognition and behavior in maladaptive ways that standard psychotherapy cannot always loosen. The REBUS model predicts that psychedelics temporarily reduce the precision of these entrenched priors, creating a window — the neuroplasticity period that follows the acute experience — in which new beliefs can be established more easily.
The Clinical Evidence: MDMA, Psilocybin, and the Phase 3 Data
The modern clinical research program for psychedelic-assisted therapy began in earnest in the early 2000s, following the scheduling moratorium that had ended research for three decades. The clinical outcomes, particularly from the MAPS MDMA trials and the Johns Hopkins and Imperial College psilocybin programs, constitute some of the most striking psychiatric treatment results in recent decades.
MAPS Phase 3 MDMA-Assisted Therapy for PTSD
MDMA (3,4-methylenedioxymethamphetamine) is not a classical psychedelic — its primary mechanism is reverse transport and release of serotonin, dopamine, and norepinephrine from presynaptic terminals rather than 5-HT2A agonism. But it produces non-ordinary states (characterized by heightened empathy, reduced fear response to threatening stimuli, and increased openness) that have been therapeutically leveraged using the same preparation-session-integration framework.
Jennifer Mitchell, Michael Bogenschutz, Alia Lancelotta, and 36 additional authors published Phase 3 results in Nature Medicine (2021, Vol. 27, pp. 1025-1033). The trial enrolled 90 participants with severe PTSD (average CAPS-5 score of 44.5, indicating severe symptomatology) who had not responded to previous treatments. Random assignment to MDMA-assisted therapy (3 preparation, 3 MDMA sessions with 80mg followed by optional 40mg supplemental dose, 9 integration sessions) or identical psychotherapy with placebo.
Results at primary endpoint (CAPS-5 change from baseline):
| Outcome | MDMA group | Placebo group |
|---|---|---|
| Mean CAPS-5 reduction | 24.4 points | 13.9 points |
| No longer met PTSD criteria | 67% | 32% |
| Clinically significant response (CAPS-5 decrease >12) | 88% | 60% |
| Effect size (Cohen's d) | 0.91 | — |
A second Phase 3 trial (MAPP2) produced comparable results: 71.2% of MDMA participants no longer met PTSD criteria at primary endpoint, versus 47.6% of placebo participants. The two trials together represent the largest randomized controlled evidence base for MDMA-assisted therapy, with effect sizes substantially larger than those achieved by any approved pharmacotherapy for PTSD.
Johns Hopkins Psilocybin for Depression
The Johns Hopkins trial published in JAMA Psychiatry (Davis, Barrett, May, Cosimano, Sepeda, Johnson, Finan, and Griffiths, 2021) enrolled 24 adults with documented moderate-to-severe major depressive disorder. Participants received preparatory therapy sessions, then two psilocybin sessions (20mg/70kg followed by 30mg/70kg two weeks later), followed by integration sessions.
Results at 4-week follow-up: 71% of participants showed a treatment response (50% or greater reduction in HAMD-17 scores). 54% met remission criteria. The effects appeared within one week of the first session — far faster than conventional antidepressants (which typically require 4-6 weeks). Extended follow-up data published subsequently showed that a significant proportion of participants maintained antidepressant effects at 12 months.
The psilocybin vs. escitalopram randomized trial (Carhart-Harris, Giribaldi, Watts, Baker-Jones, Murphy-Beiner, Murphy, Martell, Blemings, Erritzoe, and Nutt; New England Journal of Medicine, 2021) compared six weeks of standard SSRI treatment to two psilocybin sessions plus identical non-drug therapy. On the primary measure (Quick Inventory of Depressive Symptomatology, QIDS-SR-16), psilocybin was non-inferior to escitalopram, with several secondary measures (well-being, anhedonia, psychological flexibility) favoring psilocybin. The difference in speed of onset — psilocybin producing improvements within days, escitalopram requiring weeks — is particularly clinically relevant given the risks of the early-treatment period.
The Mystical Experience as Predictor
Across the Johns Hopkins therapeutic trials, one variable has emerged as the strongest and most consistent predictor of therapeutic outcome: the intensity of the "mystical experience" reported during the psilocybin session, measured using the Mystical Experience Questionnaire (MEQ30) developed by William Richards and Roland Griffiths.
The mystical experience construct captures: unity (sense of everything being one, dissolution of self/other distinction), transcendence of time and space, sense of sacredness, noetic quality (a felt sense of having encountered something objectively real and deeply true), deeply felt positive mood, paradoxicality (the experience contains contradictions that somehow cohere), and claimed ineffability (difficulty describing the experience in ordinary language).
Roland Griffiths, William Richards, Una McCann, and Robert Jesse's 2006 Psychopharmacology paper — the trial that initiated the modern research program — established that psilocybin reliably produces complete mystical experiences in a significant proportion of volunteers (56% at the highest dose in that study), and that participants rated these experiences among the most personally significant and spiritually meaningful of their lives, including at 14-month follow-up.
"The core of the mystical experience is the dramatic dissolution of ordinary self boundaries — the sense that 'I' am not separate from what I am perceiving, and that the separateness we normally maintain is conventional rather than fundamental." — Roland Griffiths, Psychopharmacology, 2006
In therapeutic trials, higher MEQ30 scores consistently predict larger and more durable therapeutic gains. In smoking cessation (Johnson et al., 2014, 2017), mystical experience scores at the psilocybin session predicted abstinence at 6-month and 12-month follow-up. In depression trials, the relationship between mystical experience intensity and antidepressant response has been observed, though it is somewhat less linear than in addiction studies. The mystical experience appears to be neither necessary nor sufficient for therapeutic benefit — patients show improvement without complete mystical experiences and some who report profound experiences do not improve — but it is the single strongest predictor identified to date.
Neuroplasticity: The Post-Session Window
The therapeutic value of psychedelic sessions may extend beyond the acute pharmacological effects through a period of heightened neuroplasticity that follows the session.
David Olson, Calvin Ly, Jonathan Greb, Lindsay Cameron, and colleagues at UC Davis published a 2018 Cell Reports paper demonstrating that a structurally diverse set of psychedelic compounds — psilocin, LSD, DMT, and several related compounds — promoted structural neural plasticity in vitro and in vivo. In cortical neurons in culture, these compounds increased dendritic spine density, dendrite arbor complexity, and synaptic density at concentrations similar to those achieved during therapeutic sessions. In rodent models, systemic administration produced similar structural changes in the prefrontal cortex and hippocampus, regions associated with mood regulation and learning. These effects were mediated by TrkB signaling (the BDNF receptor), mTOR (a kinase central to protein synthesis and synaptic plasticity), and downstream AMPA receptor trafficking.
Olson coined the term "psychoplastogens" for compounds with this profile, and noted that the structural plasticity-promoting effects are separable from the 5-HT2A-mediated psychedelic effects — non-hallucinogenic psychedelic analogs retain the plasticity-promoting effects in animal models. This finding opens the possibility of developing drugs with psychoplastogenic but not hallucinogenic profiles, and also provides a mechanism for why the therapeutic integration period (therapy delivered in the weeks after the session) may be crucial: the structural plasticity window may represent a period in which psychotherapeutic interventions produce more durable changes to neural circuits than they would outside the post-session window.
Historical Context: From Hofmann to Schedule I
Albert Hofmann's synthesis of LSD in 1938 and its accidental self-administration in 1943 triggered the first wave of psychedelic research. Sandoz distributed LSD to researchers globally through the late 1940s-1950s as "Delysid," framed as either a model psychosis or a psychotherapeutic tool. Several thousand papers were published between 1950 and 1965 on LSD's potential clinical applications — for alcoholism, anxiety, and end-of-life distress. Timothy Leary, Richard Alpert, and colleagues at Harvard conducted early research from 1960-1963, before losing their positions in a dispute over research ethics and subsequently proselytizing recreational use — an association that accelerated political backlash. Richard Nixon's Controlled Substances Act of 1970 placed LSD, psilocybin, and MDMA in Schedule I (no accepted medical use, high abuse potential), effectively ending research for three decades.
The current renaissance began in the mid-1990s when Franz Vollenweider obtained approval in Switzerland for neuroimaging studies, and in the early 2000s when Johns Hopkins, NYU, and UCLA secured DEA approval for controlled trials. MDMA's FDA Breakthrough Therapy designation in 2017 and psilocybin's in 2018 and 2019 signal regulatory recognition that the clinical evidence base has reached the threshold of serious scientific engagement.
Set and Setting: Why Context Shapes Experience
Timothy Leary's framework of "set and setting" — that the content of a psychedelic experience is shaped by the mental state (set) and the physical and social environment (setting) — was originally a heuristic derived from clinical observation rather than a mechanistic account. The REBUS model has provided a neurobiological basis.
If psychedelics operate by reducing the precision-weighting of top-down priors, they do not produce content from nowhere — they liberate the brain's associative processing from its usual top-down constraints, allowing content from the environment (the music playing, the guides' demeanor, the visual aesthetics of the room), from the person's current emotional state, and from their prior experiences and intentions to shape the direction of the loosened associative processing. A threatening environment activates the same fear circuitry that psychedelics amplify through increased prefrontal glutamate. A supportive, aesthetically prepared environment with trusted guides activates approach, safety, and openness circuits.
This is not merely subjective. Human neuroimaging studies confirm that the emotional tone of the psychedelic experience correlates with differential activation of specific subcortical circuits (amygdala for challenging/negative experiences, striatum and insula for positive/mystical ones). The preparation that contemporary clinical protocols invest heavily in — building therapeutic alliance, clarifying intentions, establishing trust with the therapist, preparing for the psychological challenges of ego dissolution — is not ritual theater. It is directly shaping the neurobiological context within which the 5-HT2A agonism will unfold.
References
- Hofmann, A. (1980). LSD: My Problem Child. McGraw-Hill.
- Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F., Babler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 9(17), 3897-3902. https://doi.org/10.1097/00001756-199812010-00024
- Carhart-Harris, R.L., Leech, R., Hellyer, P.J., Shanahan, M., Feilding, A., Tagliazucchi, E., Contreras, D., & Nutt, D. (2012). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. PNAS, 109(6), 2138-2143. https://doi.org/10.1073/pnas.1119598109
- Carhart-Harris, R., & Friston, K.J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316-344. https://doi.org/10.1124/pr.118.017160
- Griffiths, R.R., Richards, W.A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283. https://doi.org/10.1007/s00213-006-0457-5
- Davis, A.K., Barrett, F.S., May, D.G., Cosimano, M.P., Sepeda, N.D., Johnson, M.W., Finan, P.H., & Griffiths, R.R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481-489. https://doi.org/10.1001/jamapsychiatry.2020.3285
- Mitchell, J.M., Bogenschutz, M., Lancelotta, A., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27, 1025-1033. https://doi.org/10.1038/s41591-021-01336-3
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D.J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402-1411. https://doi.org/10.1056/NEJMoa2032994
- Ly, C., Greb, A.C., Cameron, L.P., Wong, J.M., Barragan, E.V., Wilson, P.C., Burbach, K.F., Soltanzadeh Zargar, S., Bennett, C., Olson, D.E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182. https://doi.org/10.1016/j.celrep.2018.05.022
- Wacker, D., Wang, S., McCorvy, J.D., Betz, R.M., Venkatakrishnan, A.J., Levit, A., Lansu, K., Schools, Z.L., Che, T., Nichols, D.E., Shoichet, B.K., Dror, R.O., & Roth, B.L. (2017). Crystal structure of an LSD-bound human serotonin receptor. Cell, 168(3), 377-389. https://doi.org/10.1016/j.cell.2016.12.033
- Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S.D., Murphy, K., Laufs, H., Leech, R., Ward, L., Bahgat, D., Sherwood, J., Fielding, A., Nutt, D., & Carhart-Harris, R. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology, 26(8), 1043-1050. https://doi.org/10.1016/j.cub.2016.02.010
Frequently Asked Questions
What is the primary pharmacological mechanism of psychedelics like psilocybin, LSD, and DMT?
The primary mechanism of classical psychedelics — psilocybin, LSD, DMT (N,N-dimethyltryptamine), and mescaline — is agonism at the 5-HT2A serotonin receptor, particularly in pyramidal neurons of the prefrontal cortex. Psilocybin is a prodrug converted by the enzyme alkaline phosphatase to psilocin, which binds the 5-HT2A receptor with high affinity. LSD similarly acts primarily through 5-HT2A agonism, though its exceptionally long duration (8-12 hours) is explained by the 'lid mechanism' documented by Brian Roth and colleagues: LSD inserts itself under an extracellular loop of the receptor structure, trapping it in an activated conformation that resists dissociation. The hallucinatory and perceptual-distorting effects of psychedelics can be blocked by prior administration of selective 5-HT2A antagonists like ketanserin, establishing 5-HT2A agonism as causally necessary for the psychedelic experience. At the cellular level, 5-HT2A activation in cortical pyramidal neurons increases glutamate release and produces 'thalamocortical dysrhythmia' — disruption of the normal thalamic filtering of sensory information to the cortex, causing normally suppressed sensory content to reach conscious awareness.
What happens to the default mode network (DMN) during a psychedelic experience?
The default mode network — a set of medially placed cortical regions including the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus, identified by Marcus Raichle in 2001 — is the network most active during self-referential thought, mind-wandering, rumination, and narrative self-construction. It is sometimes called the 'ego network' because its activity correlates strongly with the sense of being a bounded, persistent self. Robin Carhart-Harris and colleagues' 2012 PNAS paper, the first fMRI study of psilocybin, found that psilocybin produced significant decreases in DMN activity and, strikingly, that the magnitude of DMN suppression correlated with the intensity of ego dissolution reported by participants. Subsequent studies have replicated this finding across multiple psychedelic compounds. The posterior cingulate cortex (PCC), a key DMN hub, shows particularly reliable deactivation. Under psychedelics, the normal hierarchical dominance of DMN over sensory processing networks is reduced, and the functional connectivity between the DMN and the rest of the brain becomes less segregated — networks that are normally functionally distinct begin showing increased cross-network communication, which Carhart-Harris has proposed underlies the 'unconstrained' quality of psychedelic experience.
What is the REBUS model and what does it predict about how psychedelics work?
Robin Carhart-Harris and Karl Friston proposed the REBUS (Relaxed Beliefs Under pSychedelics) model in a 2019 Pharmacological Reviews paper, applying Karl Friston's predictive processing framework to psychedelic action. In predictive processing, the brain operates as a Bayesian inference machine: higher cortical levels maintain prior beliefs (predictions) about the causes of sensory input, and lower levels encode prediction errors (the difference between predicted and actual input). Normally, higher-level priors strongly constrain lower-level processing — perception is dominated by expectation. The REBUS model proposes that 5-HT2A agonism in cortical pyramidal neurons increases the precision-weighting of lower-level sensory signals relative to higher-level priors, effectively flattening the hierarchy: top-down priors are relaxed, and bottom-up sensory signals and associative content gain disproportionate influence over consciousness. This produces: perceptual enhancement and hallucination (sensory content normally filtered by prediction now reaches awareness), loosening of rigid cognitive schemas and habitual thought patterns, the unconstrained associative thinking characteristic of psychedelic experience, and the dissolution of self-as-prior (ego dissolution) because the narrative self is itself a high-level prior. Therapeutically, the REBUS model predicts that psychedelics work by temporarily loosening pathologically entrenched priors — the rigid, self-reinforcing negative beliefs and maladaptive schemas of depression, addiction, and PTSD — creating a window of heightened plasticity in which new patterns can be established.
What did the MAPS Phase 3 MDMA trials find for PTSD?
The Multidisciplinary Association for Psychedelic Studies (MAPS) conducted the first Phase 3 clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder, with results published by Jennifer Mitchell, Michael Bogenschutz, and colleagues in Nature Medicine in 2021. The study enrolled 90 participants with moderate-to-severe PTSD (mean Clinician-Administered PTSD Scale score of 44.5 at baseline) who had not responded to previous treatments. Participants received either MDMA-assisted therapy (3 preparation sessions, 3 experimental sessions with 80-120mg MDMA, 9 integration sessions) or placebo-assisted therapy with identical psychotherapy. At primary endpoint: 67% of MDMA participants no longer met PTSD diagnostic criteria (vs. 32% in the placebo group). 88% of MDMA participants showed a clinically significant response vs. 60% of placebo. The effect size was large (Cohen's d = 0.91). A second Phase 3 trial (MAPP2) produced comparable results, with 71.2% of MDMA participants no longer meeting PTSD criteria versus 47.6% of placebo participants. MDMA is not a classical psychedelic (it acts primarily through monoamine release rather than 5-HT2A agonism) but is grouped with psychedelic-assisted therapies because it produces non-ordinary states that are therapeutically leveraged through similar preparation-session-integration frameworks.
What did the Johns Hopkins psilocybin studies find for treatment-resistant depression?
Alan Davis, Frederick Barrett, Darrick May, Mary Cosimano, Nathan Sepeda, Matthew Johnson, Patrick Finan, and Roland Griffiths published results from a Johns Hopkins open-label trial of psilocybin-assisted therapy for major depressive disorder in JAMA Psychiatry in 2021. The study enrolled 24 adults with documented major depressive disorder (not treatment-resistant by standard criteria, unlike the contemporaneous Imperial College London trial). Participants received two psilocybin sessions (20mg/70kg and 30mg/70kg) two weeks apart, with preparatory and integrative sessions. At 4-week follow-up: 71% of participants showed a treatment response (50% reduction in HAMD-17 scores), and 54% met criteria for remission. The antidepressant effects were rapid — appearing within one week of the first session — and durable at 12-month follow-up in extended analyses. The Imperial College London group (Carhart-Harris, Bolstridge, Rucker, and colleagues) had published earlier open-label results in The Lancet Psychiatry in 2016 showing significant reductions in depression severity in treatment-resistant patients, with sustained effects in a subset at 3-month follow-up. These findings prompted a randomized controlled trial comparing psilocybin to escitalopram (Carhart-Harris et al., 2021, New England Journal of Medicine), which found psilocybin non-inferior to six weeks of escitalopram on the primary measure (QIDS-SR-16), with some secondary outcome advantages for psilocybin.
What is the mystical experience and why does it predict therapeutic outcomes?
Roland Griffiths, William Richards, Una McCann, and Robert Jesse's 2006 study in Psychopharmacology first documented in a controlled setting that psilocybin reliably produces mystical-type experiences — characterized by a sense of unity, transcendence of time and space, deeply felt sacredness, noetic quality (a sense of objective truth), deeply felt positive mood, and paradoxicality — which participants rated among the most personally and spiritually significant of their lives. In subsequent therapeutic research, the intensity of the mystical experience during the psilocybin session has emerged as the strongest and most consistent predictor of therapeutic outcome, across depression, addiction, and existential distress studies. Garcia-Romeu, Griffiths, and Johnson's 2014 analysis found that mystical experience scores mediated the relationship between psilocybin dose and smoking cessation at 6-month follow-up. Matthew Johnson and colleagues' 2017 smoking cessation study found mystical experience at the single-session mark to be a significant predictor of abstinence 12 months later. The mechanism is not established, but the REBUS model's prediction — that loosening of top-down priors creates a window for fundamental reorganization of self-related beliefs — provides one account: the mystical experience, involving ego dissolution and a felt sense of fundamental change, may be the phenomenological signature of a successfully loosened and restructured predictive hierarchy.
What is the neuroplasticity window after a psychedelic session?
Converging evidence from animal studies and human neuroimaging suggests that psychedelics promote structural and functional neuroplasticity beyond the acute pharmacological window. David Olson and colleagues at UC Davis (Ly et al., 2018, Cell Reports) demonstrated that psilocybin, LSD, DMT, and related compounds promoted dendritic spine growth, axonal sprouting, and synaptogenesis in cultured cortical neurons and in rodent models — effects they termed 'psychoplastogens.' These structural changes were mediated by TrkB (BDNF receptor) and mTOR signaling and occurred at concentrations comparable to those achieved therapeutically. In rodents, psychedelic administration increased BDNF (brain-derived neurotrophic factor) expression in the prefrontal cortex, hippocampus, and other regions associated with learning and mood regulation. Human neuroimaging studies have documented changes in functional connectivity that persist beyond the acute session window: Carhart-Harris and colleagues' work shows that psilocybin produces measurable changes in DMN connectivity and brain network organization that persist at 1-week follow-up in depressed patients, correlating with symptom improvement. The therapeutic implication is that psychedelic sessions open a window of heightened neuroplasticity — a period during which the brain is more amenable to learning, habit change, and the formation of new associative patterns — which integration therapy (the sessions following the experience) is designed to use constructively.